Skip to main content

Cerus Value Stock - Dividend - Research Selection

Cerus

ISIN: US1570851014 , WKN: 905249

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company\'s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Cerus Leads Our Selection Of 3 Promising Penny Stocks

2025-03-21
As U.S. stocks attempt to recover from recent downturns, with the S&P 500 and Nasdaq aiming to end their losing streaks, investors are navigating a market filled with uncertainty yet ripe with potential opportunities. Penny stocks, though often overlooked in favor of more established names, remain an intriguing investment area for those seeking growth in smaller or newer companies. By focusing on firms with strong financial foundations and clear paths to growth, investors can uncover...

Are Investors Undervaluing Cerus Corporation (NASDAQ:CERS) By 49%?

2025-03-21
Key Insights Using the 2 Stage Free Cash Flow to Equity, Cerus fair value estimate is US$2.99 Current share price of...

Tracking Baker Brothers Portfolio - Q4 2024 Update

2025-03-12
Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake increases.

Cerus secures CE mark approval for LED-based illumination device

2025-03-06
Cerus states that the CE mark represents the first regulatory approval for its “next generation” illuminator.

Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)

2025-03-05
CONCORD, Calif., March 05, 2025--Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union (EU) Medical Device Regulation (MDR). This approval allows Cerus to market the INT200 throughout the EU and in other regions that recognize the CE mark. Some countries may require additional in-country regulatory approval prior to commercializatio

Cerus Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

2025-02-22
Cerus ( NASDAQ:CERS ) Full Year 2024 Results Key Financial Results Revenue: US$180.3m (up 15% from FY 2023). Net loss...

Cerus Corp (CERS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Cash Flow

2025-02-21
Cerus Corp (CERS) reports a 15% increase in annual product revenue and achieves positive adjusted EBITDA, despite challenges in foreign exchange and gross margins.

Cerus Corporation (CERS) Q4 2024 Earnings Call Transcript

2025-02-20
Cerus Corporation (NASDAQ:CERS) Q4 2024 Earnings Call February 20, 2025 4:30 PM ETCompany ParticipantsNoopur Liffick - Investor RelationsObi Greenman -...

Cerus: Q4 Earnings Snapshot

2025-02-20
CERS) on Thursday reported a loss of $2.5 million in its fourth quarter. On a per-share basis, the Concord, California-based company said it had a loss of 1 cent. The biomedical products company posted revenue of $50.8 million in the period.

Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

2025-02-20
CONCORD, Calif., February 20, 2025--Cerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024.